BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Taltz (ixekizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Taltz (ixekizumab)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04589325-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Taltz (ixekizumab): Phase 2 readout est. (NCT04589325)
DESCRIPTION:Taltz (ixekizumab)\, phase 2.\nStudy: Ixekizumab Diabetes Inter
 vention Trial (I-DIT)\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ixekizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04589325
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789964-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Taltz (ixekizumab): Phase 1 readout est. (NCT07789964)
DESCRIPTION:Taltz (ixekizumab)\, phase 1.\nStudy: A Study to Compare the Ph
 armacokinetics\, Safety\, Tolerability\, and Immunogenicity of SB35 (Propo
 sed Ixekizumab Biosimilar) to Taltz in Healthy Participants\nEstimated pri
 mary completion: 9 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ixekizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07789964
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04537689-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taltz (ixekizumab): Phase 4 readout est. (NCT04537689)
DESCRIPTION:Taltz (ixekizumab)\, phase 4\, Psoriasis.\nStudy: Outcomes With
  Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ixekizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04537689
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443956-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Taltz (ixekizumab): Phase na readout est. (NCT07443956)
DESCRIPTION:Taltz (ixekizumab)\, phase na\, Psoriatic Arthritis.\nStudy: Co
 mbination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ixekizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07443956
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06398106-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Taltz (ixekizumab): Phase 4 readout est. (NCT06398106)
DESCRIPTION:Taltz (ixekizumab)\, phase 4\, Psoriasis.\nStudy: Proactive TDM
  Versus Standard Use of Biologics in Psoriasis\nEstimated primary completi
 on: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixe
 kizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06398106
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-97@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Taltz (ixekizumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Taltz (ixekizumab)\, phase 4\, Psoriasis.\nStudy: Utilization o
 f a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary com
 pletion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ixekizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07352566
URL:https://assetmemo.bio/drug/ixekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
